至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Proposal of De Novo Antigen Test for COVID-19: Ultrasensitive Detection of Spike Proteins of SARS-CoV-2

Diagnostics (Basel). 2020; 
Yuta Kyosei, Mayuri Namba, Sou Yamura, Rikiya Takeuchi, Noriko Aoki, Kazunari Nakaishi, Satoshi Watabe, Etsuro Ito
Products/Services Used Details Operation
Catalog Antibody … 91339; Active Motif, Carlsbad, CA, USA), and the secondary antibody was AM002414 (Cat No. 91349; Active Motif) [15]. The antigen was spike protein (S1) of SARS-CoV-2 (human cell source, 78.3 kDa, Cat No. Z03501; GenScript USA, Piscataway, NJ, USA) … Get A Quote

摘要

Polymerase chain reaction (PCR)-based antigen tests are technically difficult, time-consuming, and expensive, and may produce false negative results requiring follow-up confirmation with computed tomography. The global coronavirus disease 2019 (COVID-19) pandemic has increased the demand for accurate, easy-to-use, rapid, and cost-effective antigen tests for clinical application. We propose a de novo antigen test for diagnosing COVID-19 using the combination of sandwich enzyme-linked immunosorbent assay and thio-nicotinamide adenine dinucleotide (thio-NAD) cycling. Our test takes advantage of the spike proteins specific to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. The limit of detec... More

关键词

COVID-19, SARS-CoV-2, spike protein, thio-NAD cycling, ultrasensitive ELISA